The Subrenal Capsule Assay as a Predictor of Tumour Response in Gynaecological Oncology
Present cancer treatment requires selection of therapy for individual patients on the basis of clinical trials in large, heterogeneous populations of patients. Recent attention, however, has focused on the possibility of determining the susceptibility of an individual human malignancy to a therapeutic manoeuvre by means of prior laboratory testing of the tumour. The oestrogen receptor protein assay has demonstrated the clinical utility of this approach, by allowing selection of those patients more likely to respond to hormonal manipulation and exclusion of those patients unlikely to respond . With regard to chemotherapeutic agents, attention has focused on the human tumour stem cell assay developed by Salmon and co-workers  and on the subrenal capsule assay developed by Bogden et al. .
KeywordsPredictive Accuracy Endometrial Carcinoma Gynaecological Oncology Clinical Response Rate Human Tumor Xenograft
Unable to display preview. Download preview PDF.
- 3.Bogden AE, Cobb WR, Kelton DE, LePage DJ, Remington K, Cote TH (1978) A six-day subrenal capsule assay for drug screening using the normal immunocompetent mouse as host for human tumor xenografts (Abstr). Proc AACR and ASCO 19:105Google Scholar
- 6.Bogden AE, Cobb WR, LePage DL, Kelton DE (1981) Reproducibility of chemotherapy response profiles of human tumor explants in the 6-day subrenal capsule (SRC) assay (Abstr). Proc AACR and ASCO 22:224Google Scholar
- 8.Griffin TW, Bogden AE, Reich SD et al. (to be published) Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. CancerGoogle Scholar